TY  - JOUR
AU  - Rajkov, Branislava
AU  - Zdravković, Marija
AU  - Ninić, Ana
AU  - Brajković, Milica
AU  - Klašnja, Slobodan
AU  - Gardijan, Vera
AU  - Memon, Lidija
AU  - Munjas, Jelena
AU  - Mihajlović, Marija
AU  - Spasojević-Kalimanovska, Vesna
AU  - Radosavljević, Vojislav
AU  - Sopić, Miron
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4551
AB  - Purpose: Obstructive sleep apnea (OSA) is characterised by increased systemic inflammation, and is often accompanied with type 2 diabetes mellitus (T2DM) and cardiovascular disease. The aim of this investigation was to evaluate gene expression of resistin, its receptor CAP1 and CD36 as the indicators of the inflammatory changes in PBMCs in relation to the severity of OSA, and the presence of type 2 diabetes mellitus (T2DM) in OSA. Methods: Severity of OSA was defined by the apnea/hypopnea index (AHI): AHI < 30: mild to moderate OSA (MM-OSA), AHI ≥ 30: severe OSA (S-OSA). Presence of T2DM was captured: OSA with T2DM (OSA + T2DM), OSA without T2DM (OSA-T2DM). PBMC resistin, CAP1, and CD36 mRNA were determined by real-time PCR. Results: Resistin mRNA was significantly upregulated in S-OSA (N = 54) compared to the MM-OSA (N = 52, P = 0.043); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.302; P = 0.166, respectively). Resistin mRNA was significantly upregulated in OSA + T2DM (N = 29) compared to the OSA-T2DM (N = 77, P = 0.029); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.662; P = 0.108, respectively). AHI and T2DM were independent predictors of resistin mRNA above the 75th percentile (OR = 3.717 [1.152–11.991]; OR = 3.261 [1.000–10.630], P = 0.042 respectively). Conclusion: Resistin gene upregulation in S-OSA indicates its possible contribution to increased inflammation in S-OSA and makes it a possible marker of the disease severity. Resistin gene upregulation in OSA + T2DM suggests that a joint effect of these two comorbidities may have a major contribution to increased inflammation and complications that arise from this state.
PB  - Springer Nature
T2  - Sleep and Breathing
T1  - Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus
DO  - 10.1007/s11325-023-02809-0
ER  - 

@article{
author = "Rajkov, Branislava and Zdravković, Marija and Ninić, Ana and Brajković, Milica and Klašnja, Slobodan and Gardijan, Vera and Memon, Lidija and Munjas, Jelena and Mihajlović, Marija and Spasojević-Kalimanovska, Vesna and Radosavljević, Vojislav and Sopić, Miron",
year = "2023",
abstract = "Purpose: Obstructive sleep apnea (OSA) is characterised by increased systemic inflammation, and is often accompanied with type 2 diabetes mellitus (T2DM) and cardiovascular disease. The aim of this investigation was to evaluate gene expression of resistin, its receptor CAP1 and CD36 as the indicators of the inflammatory changes in PBMCs in relation to the severity of OSA, and the presence of type 2 diabetes mellitus (T2DM) in OSA. Methods: Severity of OSA was defined by the apnea/hypopnea index (AHI): AHI < 30: mild to moderate OSA (MM-OSA), AHI ≥ 30: severe OSA (S-OSA). Presence of T2DM was captured: OSA with T2DM (OSA + T2DM), OSA without T2DM (OSA-T2DM). PBMC resistin, CAP1, and CD36 mRNA were determined by real-time PCR. Results: Resistin mRNA was significantly upregulated in S-OSA (N = 54) compared to the MM-OSA (N = 52, P = 0.043); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.302; P = 0.166, respectively). Resistin mRNA was significantly upregulated in OSA + T2DM (N = 29) compared to the OSA-T2DM (N = 77, P = 0.029); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.662; P = 0.108, respectively). AHI and T2DM were independent predictors of resistin mRNA above the 75th percentile (OR = 3.717 [1.152–11.991]; OR = 3.261 [1.000–10.630], P = 0.042 respectively). Conclusion: Resistin gene upregulation in S-OSA indicates its possible contribution to increased inflammation in S-OSA and makes it a possible marker of the disease severity. Resistin gene upregulation in OSA + T2DM suggests that a joint effect of these two comorbidities may have a major contribution to increased inflammation and complications that arise from this state.",
publisher = "Springer Nature",
journal = "Sleep and Breathing",
title = "Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus",
doi = "10.1007/s11325-023-02809-0"
}

Rajkov, B., Zdravković, M., Ninić, A., Brajković, M., Klašnja, S., Gardijan, V., Memon, L., Munjas, J., Mihajlović, M., Spasojević-Kalimanovska, V., Radosavljević, V.,& Sopić, M.. (2023). Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus. in Sleep and Breathing
Springer Nature..
https://doi.org/10.1007/s11325-023-02809-0

Rajkov B, Zdravković M, Ninić A, Brajković M, Klašnja S, Gardijan V, Memon L, Munjas J, Mihajlović M, Spasojević-Kalimanovska V, Radosavljević V, Sopić M. Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus. in Sleep and Breathing. 2023;.
doi:10.1007/s11325-023-02809-0 .

Rajkov, Branislava, Zdravković, Marija, Ninić, Ana, Brajković, Milica, Klašnja, Slobodan, Gardijan, Vera, Memon, Lidija, Munjas, Jelena, Mihajlović, Marija, Spasojević-Kalimanovska, Vesna, Radosavljević, Vojislav, Sopić, Miron, "Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus" in Sleep and Breathing (2023),
https://doi.org/10.1007/s11325-023-02809-0 . .

TY  - JOUR
AU  - Milojević, Ana
AU  - Zdravković, Marija
AU  - Brajković, Milica
AU  - Memon, Lidija
AU  - Gardijan, Vera
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Stefanović, Aleksandra
AU  - Mihajlović, Marija
AU  - Ivanišević, Jasmina
AU  - Bogavac-Stanojević, Nataša
AU  - Radosavljević, Vojislav
AU  - Spasojević-Kalimanovska, Vesna
AU  - Ninić, Ana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4199
AB  - Objectives: Obstructive sleep apnea (OSA) is a common condition closely related to obesity, insulin resistance, dyslipidemia, and cardiovascular disease. The aim of this study was to explore the possible relationship between OSA and proprotein convertase subtilisin/kexin type 9 (PCSK9). Methods: Full-night polysomnography was performed on 150 participants who were divided into three groups: controls, OSA patients on statin therapy, and OSA patients not on statin therapy. Biochemical markers, plasma low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclasses, and PCSK9 were determined. Results: PCSK9 was highest in OSA patients on statins compared to the control group and to OSA patients not on statins (p = 0.036 and p = 0.039, respectively), after adjustment for body mass index (BMI). LDL diameter was greater in OSA patients not on statins compared to OSA patients on statins (p = 0.032). PCSK9 was highest in the group of patients with all three risk factors (diagnosed OSA, statins, BMI ≥25 kg/m2) compared to groups with no, one, and two risk factors (p = 0.031, p = 0.001, and p = 0.029, respectively). Presence of OSA, statin therapy, and BMI ≥25 kg/m2 when combined were independently associated with higher levels of PCSK9 when adjusted for antihypertensive therapy, small dense LDL, and HDL 3c subclass (odds ratio = 2.849; interquartile range [1.026–7.912], p = 0.044). Conclusion: Statin therapy was closely related to PCSK9. OSA along with obesity and statin use induces elevation of PCSK9.
PB  - S. Karger AG Basel
T2  - Medical Principles and Practice
T1  - Effects of Apnea, Obesity, and Statin Therapy on
Proprotein Convertase Subtilisin/Kexin 9 Levels
in Patients with Obstructive Sleep Apnea
VL  - 31
IS  - 3
SP  - 293
EP  - 300
DO  - 10.1159/000524087
ER  - 

@article{
author = "Milojević, Ana and Zdravković, Marija and Brajković, Milica and Memon, Lidija and Gardijan, Vera and Vekić, Jelena and Zeljković, Aleksandra and Stefanović, Aleksandra and Mihajlović, Marija and Ivanišević, Jasmina and Bogavac-Stanojević, Nataša and Radosavljević, Vojislav and Spasojević-Kalimanovska, Vesna and Ninić, Ana",
year = "2022",
abstract = "Objectives: Obstructive sleep apnea (OSA) is a common condition closely related to obesity, insulin resistance, dyslipidemia, and cardiovascular disease. The aim of this study was to explore the possible relationship between OSA and proprotein convertase subtilisin/kexin type 9 (PCSK9). Methods: Full-night polysomnography was performed on 150 participants who were divided into three groups: controls, OSA patients on statin therapy, and OSA patients not on statin therapy. Biochemical markers, plasma low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclasses, and PCSK9 were determined. Results: PCSK9 was highest in OSA patients on statins compared to the control group and to OSA patients not on statins (p = 0.036 and p = 0.039, respectively), after adjustment for body mass index (BMI). LDL diameter was greater in OSA patients not on statins compared to OSA patients on statins (p = 0.032). PCSK9 was highest in the group of patients with all three risk factors (diagnosed OSA, statins, BMI ≥25 kg/m2) compared to groups with no, one, and two risk factors (p = 0.031, p = 0.001, and p = 0.029, respectively). Presence of OSA, statin therapy, and BMI ≥25 kg/m2 when combined were independently associated with higher levels of PCSK9 when adjusted for antihypertensive therapy, small dense LDL, and HDL 3c subclass (odds ratio = 2.849; interquartile range [1.026–7.912], p = 0.044). Conclusion: Statin therapy was closely related to PCSK9. OSA along with obesity and statin use induces elevation of PCSK9.",
publisher = "S. Karger AG Basel",
journal = "Medical Principles and Practice",
title = "Effects of Apnea, Obesity, and Statin Therapy on
Proprotein Convertase Subtilisin/Kexin 9 Levels
in Patients with Obstructive Sleep Apnea",
volume = "31",
number = "3",
pages = "293-300",
doi = "10.1159/000524087"
}

Milojević, A., Zdravković, M., Brajković, M., Memon, L., Gardijan, V., Vekić, J., Zeljković, A., Stefanović, A., Mihajlović, M., Ivanišević, J., Bogavac-Stanojević, N., Radosavljević, V., Spasojević-Kalimanovska, V.,& Ninić, A.. (2022). Effects of Apnea, Obesity, and Statin Therapy on
Proprotein Convertase Subtilisin/Kexin 9 Levels
in Patients with Obstructive Sleep Apnea. in Medical Principles and Practice
S. Karger AG Basel., 31(3), 293-300.
https://doi.org/10.1159/000524087

Milojević A, Zdravković M, Brajković M, Memon L, Gardijan V, Vekić J, Zeljković A, Stefanović A, Mihajlović M, Ivanišević J, Bogavac-Stanojević N, Radosavljević V, Spasojević-Kalimanovska V, Ninić A. Effects of Apnea, Obesity, and Statin Therapy on
Proprotein Convertase Subtilisin/Kexin 9 Levels
in Patients with Obstructive Sleep Apnea. in Medical Principles and Practice. 2022;31(3):293-300.
doi:10.1159/000524087 .

Milojević, Ana, Zdravković, Marija, Brajković, Milica, Memon, Lidija, Gardijan, Vera, Vekić, Jelena, Zeljković, Aleksandra, Stefanović, Aleksandra, Mihajlović, Marija, Ivanišević, Jasmina, Bogavac-Stanojević, Nataša, Radosavljević, Vojislav, Spasojević-Kalimanovska, Vesna, Ninić, Ana, "Effects of Apnea, Obesity, and Statin Therapy on
Proprotein Convertase Subtilisin/Kexin 9 Levels
in Patients with Obstructive Sleep Apnea" in Medical Principles and Practice, 31, no. 3 (2022):293-300,
https://doi.org/10.1159/000524087 . .

TY  - JOUR
AU  - Zeljković, Aleksandra
AU  - Milojević, Ana
AU  - Vladimirov, Sandra
AU  - Zdravković, Marija
AU  - Memon, Lidija
AU  - Brajković, Milica
AU  - Gardijan, Vera
AU  - Gojković, Tamara
AU  - Stefanović, Aleksandra
AU  - Miljković-Trailović, Milica
AU  - Spasojević-Kalimanovska, Vesna
AU  - Ninić, Ana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4322
AB  - Background and aims: Obstructive sleep apnea (OSA) is closely linked to obesity and related adverse metabolic changes, including dyslipidemia. However, it is not clear whether OSA is an independent contributing factor to dyslipidemia, or the observed association is a reflection of a concomitant presence of obesity. Additionally, dyslipidemia is usually evaluated through measurement of parameters of routine lipid status, while more precise evaluation of lipid homeostasis is rarely performed in OSA. In this study, we analyzed markers of cholesterol synthesis and absorption in patients with OSA with respect to the presence of obesity and the disease severity. Methods and results: This study enrolled 116 OSA patients. Concentrations of non-cholesterol sterols (NCS), measured by LC-MS/MS, were used as markers of cholesterol synthesis and absorption. Apnea-hypopnea index (AHI) and oxygen saturation (SaO2) were utilized as markers of OSA severity. Serum lipid status parameters were determined by routine enzymatic methods. Markers of cholesterol synthesis were increased (P = 0.005), whilst markers of cholesterol absorption decreased (P = 0.001) in obese OSA patients. Cholesterol synthesis/absorption ratio was elevated in obese subjects (P < 0.001). Concentration of cholesterol synthesis marker lathosterol was significantly higher in subjects with severe OSA (P = 0.014) and we observed a trend of decreased cholesterol absorption in these patients. AHI was revealed as an independent determinant of lathosterol concentration (P = 0.022). Conclusions: Our results suggest that the presence of obesity and severe forms of OSA is characterized by elevated endogenous cholesterol synthesis. AHI was singled out as an independent determinant of the serum level of cholesterol synthesis marker lathosterol.
PB  - Elsevier B.V.
T2  - Nutrition, Metabolism and Cardiovascular Diseases
T1  - Alterations of cholesterol synthesis and absorption in obstructive sleep apnea: Influence of obesity and disease severity
VL  - 32
IS  - 12
SP  - 2848
EP  - 2857
DO  - 10.1016/j.numecd.2022.09.006
ER  - 

@article{
author = "Zeljković, Aleksandra and Milojević, Ana and Vladimirov, Sandra and Zdravković, Marija and Memon, Lidija and Brajković, Milica and Gardijan, Vera and Gojković, Tamara and Stefanović, Aleksandra and Miljković-Trailović, Milica and Spasojević-Kalimanovska, Vesna and Ninić, Ana",
year = "2022",
abstract = "Background and aims: Obstructive sleep apnea (OSA) is closely linked to obesity and related adverse metabolic changes, including dyslipidemia. However, it is not clear whether OSA is an independent contributing factor to dyslipidemia, or the observed association is a reflection of a concomitant presence of obesity. Additionally, dyslipidemia is usually evaluated through measurement of parameters of routine lipid status, while more precise evaluation of lipid homeostasis is rarely performed in OSA. In this study, we analyzed markers of cholesterol synthesis and absorption in patients with OSA with respect to the presence of obesity and the disease severity. Methods and results: This study enrolled 116 OSA patients. Concentrations of non-cholesterol sterols (NCS), measured by LC-MS/MS, were used as markers of cholesterol synthesis and absorption. Apnea-hypopnea index (AHI) and oxygen saturation (SaO2) were utilized as markers of OSA severity. Serum lipid status parameters were determined by routine enzymatic methods. Markers of cholesterol synthesis were increased (P = 0.005), whilst markers of cholesterol absorption decreased (P = 0.001) in obese OSA patients. Cholesterol synthesis/absorption ratio was elevated in obese subjects (P < 0.001). Concentration of cholesterol synthesis marker lathosterol was significantly higher in subjects with severe OSA (P = 0.014) and we observed a trend of decreased cholesterol absorption in these patients. AHI was revealed as an independent determinant of lathosterol concentration (P = 0.022). Conclusions: Our results suggest that the presence of obesity and severe forms of OSA is characterized by elevated endogenous cholesterol synthesis. AHI was singled out as an independent determinant of the serum level of cholesterol synthesis marker lathosterol.",
publisher = "Elsevier B.V.",
journal = "Nutrition, Metabolism and Cardiovascular Diseases",
title = "Alterations of cholesterol synthesis and absorption in obstructive sleep apnea: Influence of obesity and disease severity",
volume = "32",
number = "12",
pages = "2848-2857",
doi = "10.1016/j.numecd.2022.09.006"
}

Zeljković, A., Milojević, A., Vladimirov, S., Zdravković, M., Memon, L., Brajković, M., Gardijan, V., Gojković, T., Stefanović, A., Miljković-Trailović, M., Spasojević-Kalimanovska, V.,& Ninić, A.. (2022). Alterations of cholesterol synthesis and absorption in obstructive sleep apnea: Influence of obesity and disease severity. in Nutrition, Metabolism and Cardiovascular Diseases
Elsevier B.V.., 32(12), 2848-2857.
https://doi.org/10.1016/j.numecd.2022.09.006

Zeljković A, Milojević A, Vladimirov S, Zdravković M, Memon L, Brajković M, Gardijan V, Gojković T, Stefanović A, Miljković-Trailović M, Spasojević-Kalimanovska V, Ninić A. Alterations of cholesterol synthesis and absorption in obstructive sleep apnea: Influence of obesity and disease severity. in Nutrition, Metabolism and Cardiovascular Diseases. 2022;32(12):2848-2857.
doi:10.1016/j.numecd.2022.09.006 .

Zeljković, Aleksandra, Milojević, Ana, Vladimirov, Sandra, Zdravković, Marija, Memon, Lidija, Brajković, Milica, Gardijan, Vera, Gojković, Tamara, Stefanović, Aleksandra, Miljković-Trailović, Milica, Spasojević-Kalimanovska, Vesna, Ninić, Ana, "Alterations of cholesterol synthesis and absorption in obstructive sleep apnea: Influence of obesity and disease severity" in Nutrition, Metabolism and Cardiovascular Diseases, 32, no. 12 (2022):2848-2857,
https://doi.org/10.1016/j.numecd.2022.09.006 . .